Title |
A profile of enzalutamide for the treatment of advanced castration resistant prostate cancer
|
---|---|
Published in |
Cancer Management and Research, June 2015
|
DOI | 10.2147/cmar.s50585 |
Pubmed ID | |
Authors |
Rosa Greasley, Mohammad Khabazhaitajer, Derek J Rosario |
Abstract |
Recent advances in understanding the mechanisms underlying the development and progression of castration resistant prostate cancer from androgen-sensitive prostate cancer have provided new avenues exploring efficacious therapies in a disease which is the second leading cause of cancer deaths among men in the western world. In the evolution of second generation anti-androgens, enzalutamide, a novel androgen-receptor signaling inhibitor, has emerged targeting multiple steps within the androgenic stimulation pathway. This review discusses what is currently known of the mechanisms surrounding castration resistant prostate cancer development and the current human clinical trials to determine whether enzalutamide presents a new hope for men with advanced prostate cancer. The issues of therapy resistance, withdrawal effects and cross-resistance are briefly touched upon. |
X Demographics
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Geographical breakdown
Country | Count | As % |
---|---|---|
Canada | 1 | 25% |
Unknown | 3 | 75% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 3 | 75% |
Practitioners (doctors, other healthcare professionals) | 1 | 25% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 38 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 9 | 24% |
Student > Bachelor | 8 | 21% |
Other | 3 | 8% |
Student > Master | 3 | 8% |
Researcher | 2 | 5% |
Other | 5 | 13% |
Unknown | 8 | 21% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 9 | 24% |
Agricultural and Biological Sciences | 5 | 13% |
Chemistry | 4 | 11% |
Biochemistry, Genetics and Molecular Biology | 3 | 8% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 5% |
Other | 4 | 11% |
Unknown | 11 | 29% |